Thromboxane A2, the predominant cyclo-oxygenase product of arachidonic acid in platelets, is a potent vasoconstrictor and platelet agonist. Analysis of urinary metabolites by gas chromatography and mass spectrometry is a specific non-invasive method of measuring the biosynthesis of thromboxane that avoids the problem of platelet activation ex vivo. Excretion of the major urinary thromboxane metabolite, 2,3-dinor-thromboxane B2, was significantly increased (p<0-001) in 10 patients (nine women) with systemic sclerosis complicated by Raynaud's phenomenon compared with healthy controls (486 (SD 88) v 162 (38) ng/g creatinine) and increased further in the patients (to 1007 (212) ng/g creatinine) during application of a cold stimulus sufficient to induce digital vasoconstriction. Consistent with an increase in platelet-vascular interactions in vivo, excretion of a prostacyclin metabolite was also significantly increased (p<0-005) in the patients with systemic sclerosis (248 (39) v 112 (10) ng/g creatinine) and tended to increase further on cooling.
Introduction
Raynaud's phenomenon is characterised by episodic, exaggerated constriction of the small digital arteries and arterioles in response to cold or emotional stress. ' Studies of Raynaud's phenomenon associated with systemic sclerosis have shown histological changes of intimal hyperplasia and severe fibrosis in the veins23 and an excessive reduction in peripheral blood flow after administration of vasoconstrictors. 4 Thromboxane A2, the predominant cyclo-oxygenase metabolite formed from arachidonic acid in the platelet,' is a potent vasoconstrictor and platelet agonist. Because of this and the evolving therapeutic regimens designed selectively to inhibit synthesis of thromboxane' or to antagonise its action,' we studied the formation of thromboxane in vivo in patients with systemic sclerosis complicated by Raynaud's phenomenon. We used a specific, sensitive, and non-invasive approach to measure the biosynthesis of thromboxane to see whether it is increased in such patients and whether induction of Raynaud's phenomenon by exposure to cold is associated with a further increase.
Patients and methods
Ten patients (nine women and one man) with systemic sclerosis (scleroderma) complicated by symptomatic Raynaud's phenomenon participated in the study, which was approved by the Committee for the Protection of Human Subjects at Vanderbilt University Medical Center. Ages ranged from 36 to 60 (mean 45 4) years and each patient fulfilled the criteria of the American Rheumatism Association for a diagnosis of systemic sclerosis.' Patients excluded had a clinical history or laboratory evidence (electrocardiogram and routine automated biochemical screen) of ischaemic heart disease or renal impairment (serum creatinine concentration >133 [imol/l (>1 5 mg/100 ml)) or were taking antiplatelet drugs. All patients studied were non-smokers and refrained from taking aspirin for at least two weeks before the study.
The patients and 10 healthy controls matched for age and sex were studied before and after central cooling had been induced with a cooling blanket (Aquamatic-K-thermia, Gorman-Rupp, Bellville, Ohio). Cooling continued for 30 minutes or until Raynaud's phenomenon developed, which was observed in all patients. Care was taken to ensure that the maximum fall in the subject's normal oral temperature did not exceed 3°F. Blood samples were taken before cooling for measurement of plasma P3 thromboglobulin and platelet factor 4, serum thromboxane B2, and platelet aggregation in response to arachidonic acid. Urine was collected for 24 hours before the study, followed by a second collection corresponding to the time of cooling, for measurement of the major urinary metabolites of thromboxane, 2,3-dinor-thromboxane B2 and prostacyclin, 2,3-dinor-6-keto-prostaglandin Fl,,.
Biochemical analyses-2,3-Dinor-thromboxane B2 and 2,3-dinor-6-ketoprostaglandin Fl,, were measured by stable isotope dilution assays using gas chromatography and mass spectrometry in the negative ion-chemical ionisation mode.9 '°Serum thromboxane B2 generation in vitro was measured by radioimmunoassay using the method of Patrono et al." Platelet function tests Platelet aggregation was studied using a light transmission method in a Payton dual channel aggregometer. 12 The threshold aggregating concentration for arachidonic acid was determined (defined as the minimum concentration of arachidonic acid producing a greater than 70% increase in light transmission). The platelet cc granule constituents were measured by radioimmunoassay (Amersham and Abbott Laboratories).
Statistical analyses were performed using a non-parametric method (the Wilcoxon rank sum test) to avoid making assumptions about the distribution of the variables.
Results
Basal excretion of 2,3-dinor-thromboxane B2 was significantly increased in the patients with systemic sclerosis and Raynaud's phenomenon (p<0001) compared with the healthy controls (486 (SD 88) v 162 (38) ng/g creatinine). Basal excretion of 2,3-dinor-6-keto-prostaglandin F1,, was also more than double in the patients compared with the controls (248 (39) v 112 (10) ng/g creatinine; p<0O005). Both plasma (i thromboglobulin concentration (57 (16) v 14 (2) ftg/l; p<0005) and platelet factor concentration (43 (14) v 6 (1) ,ug/l; p<0005) were significantly higher in the patients. The threshold concentration for platelet aggregation in response to arachidonic acid was also significantly lower (p<0005) in the patients (0-16 (0-04) mmol/1) compared with the healthy subjects (0-38 (0-06) mmol/1). considerably raised in the patients. This may reflect the presence of platelet activation in vivo or increased sensitivity of platelets obtained from patients with systemic sclerosis to activation ex vivo. The clearance of platelet factor 4 from plasma is extremely rapid whereas the plasma half life of f thromboglobulin is more prolonged (about 100 minutes). Measurement of both platelet proteins in the same sample may, therefore, permit distinction between platelet activation in vivo and ex vivo.2" The coincidental increase in platelet factor 4 suggests that the appreciable increase in P Mean (SD) excretions of 2,3-dinor-thromboxane B2 and 2,3-dinor-6-keto-prostaglandin F,(, ( 345 In conclusion, endogenous formation of thromboxane A2 is enhanced in patients with systemic sclerosis, and precipitation of Raynaud's phenomenon by exposure to cold is associated with a further increase in biosynthesis of thromboxane. A coincidental increase in biosynthesis of prostacyclin in these patients may reflect a homoeostatic mechanism whereby the vasospastic and platelet aggregatory actions of thromboxane A2 are attenuated. These results provide a rationale for evaluating treatment that inhibits thromboxane A2 while preserving the synthesis of prostacyclin.
Introduction
The mean birth weight of white infants differs from that of infants born to mothers from other ethnic groups, especially Asian. 1-3 Because established percentile charts relate to white infants, the criterion of weight alone cannot be used to identify accurately intrauterine growth retardation in infants from other ethnic groups. We measured the ratio ofmid-arm circumference to occipitofrontal circumference in normal full term babies from different ethnic
